Overview of ALK fusion partners identified in ALCL, ALK+.
Anaplastic large cell lymphoma (ALCL) describes a distinct group of T cell lymphomas characterised by cell surface expression of CD30. At least three entities of ALCL exist, with similar cellular morphology but varying clinical courses and pathology: systemic ALCL, anaplastic lymphoma kinase (ALK)-positive, systemic ALCL ALK− and primary cutaneous ALCL. A fourth provisional entity associated with breast implants has been proposed, named breast implant-associated (BIA)-ALCL. ALCL have varying clinical outcomes, affect both children and adults, and range from being well-characterised at the genetic level to relatively unknown, predominantly due to the relative rarity of this group of malignancies. Current therapeutic approaches include standard chemotherapeutic agents as well as novel drugs including monoclonal antibodies and kinase inhibitors.
- anaplastic large cell lymphoma
- anaplastic lymphoma kinase
- tyrosine kinase inhibitors
- peripheral T cell lymphoma
Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a CD30-positive (or ki-1+) histiocytic lymphoma, later re-classified as a distinct clinical entity, ALCL . The presence of a chromosomal translocation in this malignancy was described independently by several authors in 1989–1990 [2, 3, 4, 5]. This was further refined in 1994 on cloning of the t(2;5)(p23;q35) translocation breakpoint product, identified as a fusion protein of Nucleophosmin 1 (NPM) and anaplastic lymphoma kinase (ALK), the latter a previously uncharacterized protein named after the disease from which it was cloned . Sometime later in 2008, systemic (s) ALCL was divided into two provisional entities: ALCL, ALK+ and ALCL, ALK− which were confirmed as distinct entities in the revised 4th edition of the WHO classification of tumours of haemopoietic and lymphoid tissues . The revised 4th edition also includes a new provisional entity of ALCL associated with breast implants, breast implant-associated (BIA)-ALCL which may consist of at least two clinically distinguishable forms, if not a spectrum of disease, ranging from sub-capsular seroma fluid to aggressive, infiltrating masses with good and poor prognoses respectively [8, 9]. As well as systemic forms of the disease, there exists a cutaneous type belonging to the class of primary cutaneous CD30-positive T cell lymphoproliferative disorders—primary cutaneous (pc) ALCL . In this chapter, the clinical and pathological presentations of each of these disease entities will be presented and discussed as will the biology underlying these malignancies.
2. Systemic ALCL
2.1 Clinical course
The large majority of ALCL, ALK+ are diagnosed in a younger patient population with a median age of 10.2–11 and have a relatively good prognosis (>80% overall survival; OS) [10, 11, 12, 13, 14, 15]. In contrast ALCL, ALK− more often affects an older demographic (40–65 years of age) and has a poor prognosis (<50% OS) [16, 17, 18, 19]. Whether these different clinical outcomes are age-related or due to inherent properties of the malignancies remains to be determined although in support of the latter, ALK− ALCL carrying DUSP22 rearrangements have been reported to have a superior 5-year OS of 90% (compared to 17% for TP63 rearranged cases and 42% for ALK−/DUSP22−/TP63− cases) although if patients are stratified according to age rather than ALK status, the outcome in response to treatment is the same [17, 19, 20]. The relatively high survival rates of patients diagnosed with ALCL, ALK+ may also be attributable to the host immune response whereby cytotoxic T lymphocytes, helper T cells and B cells responding to ALK have been detected in patients [21, 22]. Patients with ALCL, ALK+ mount an immune response to the ALK protein in the form of a humoral antibody response . In fact, the titre of ALK autoantibodies in a patient’s serum can be predictive of outcome with an inverse correlation between ALK antibodies and relapse . This prognostic factor can be extended further when combined with the presence or absence of minimal disseminated disease (MDD), with children having low ALK autoantibody titres combined with presence of MDD being of high risk, with the converse indicative of low risk .
2.2 Histopathological presentation and immunophenotype
ALCL spans a broad morphological spectrum with sub-types including common (65%), small cell and lymphohistiocytic variants (32% combined) with the latter constituting a poor prognostic variable [26, 27, 28]. The unifying feature of ALCL is the presence of CD30 expression on the surface of the tumour cells, particularly the larger ones. CD30 is a marker of activated immune cells but does not distinguish between a T or B cell origin when applied in isolation. Hence, for a diagnosis of a T cell lymphoma, a cell surface protein, or combination of proteins unique to T cells must be detected. In this regard, many ALCL express CD4, CD2 and/or CD5 but often lack CD3. The positive expression of CD4 in the absence of CD8 combined with the presence of cytotoxic proteins such as TIA-1, Granzyme B and/or perforin is at odds with the presumed cytotoxic T cell origin of ALCL [7, 29]. However, in some cases, no T cell specific proteins are detectable and these are categorised as being ‘null cell’, although the majority demonstrate molecular rearrangements of the T cell receptor (TCR) .
2.3 Underlying genetic alterations
2.3.1 ALCL, ALK+
ALCL is, in general, a genetically stable cancer with few common defining genetic alterations besides translocations involving ALK [31, 32]. In this regard, the t(2;5)(p23;q35) generating NPM-ALK at the breakpoint is the most common event with many variants having been published over the years (Table 1) . The common expression of NPM-ALK, and its nuclear and cytoplasmic location as opposed to cytoplasmic-alone position as seen with many of the other variants, may account for its predominance in ALCL, ALK+; nuclear location may provide a competitive advantage over cytoplasmic alone. Alternatively, the
|Chromosomal alteration||Fusion protein||Cellular location||References|
|t(2;5)(p23;q35)||NPM-ALK||Nucleus and cytoplasm||[2, 3, 4, 5, 6]|
|t(2;3)(p23;q12.2)||TFG-ALK (short, long and extra-long isoforms)||Cytoplasm||[134, 135]|
|t(2;17)(p23;q23)||CLTC-ALK||Cytoplasm (granular)||[140, 141]|
While ALK translocations are diagnostic of ALCL, ALK+ and are central to disease pathogenesis, the role of other contributing mutations is largely unknown as few consistent genetic abnormalities besides those generating ALK translocations have been reported. This may, in part, be due to the plethora a cancer hallmarks that can be driven by NPM-ALK alone (Figure 1). However, array comparative genomic hybridization (aCGH) studies have highlighted some commonalities [31, 32]. For example, gains of chromosomes 7, 6q, 17p, 17q24-qter and losses of chromosomes 4q13-q21, 11q14 and 13q although the significance of these is unknown . However, a higher number of genomic imbalances as detected by aCGH at a resolution of 1 MB, has been associated with a worse prognosis .
The recognition of NPM-ALK as a driving oncogenic event and the paucity of other reported consistent genomic/genetic abnormalities in ALCL, ALK+ has led to studies of the epigenetics of ALCL [31, 49, 50]. Profiling of CpG methylation in ALCL defined a number of genes silenced in these malignancies including the TCR signalling-related proteins Zap70, LAT, CD3ε, SLP76 and the IL2Rγ chain [43, 45, 46, 47, 49, 51]. Given that NPM-ALK can substitute for signalling normally induced via an engaged TCR, activation of these proximal TCR signalling proteins may be detrimental to cell survival resulting in their evolutionary down-regulation [38, 52]. Furthermore, a number of miRNA have been implicated in tumorigenesis including miR17-92, miR135b, miR29a and miR16 [53, 54, 55, 56].
2.3.2 ALCL, ALK−
By their very definition, ALCL, ALK− lack expression of ALK fusion proteins, but until recently, few studies had found major contributory and consistent mutations. DUSP22 rearrangements leading to loss of expression of DUSP22 have been reported in as many as 30% of cases and activating
BIA-ALCL is a relatively new addition to the spectrum of ALCL, although the first case was reported in 1997, but did not receive much attention until further cases were identified and published, and the FDA acknowledged an association in 2011 [70, 71]. In March 2015, the French health minister issued a warning following reports of 18 cases in France . A further follow-up report released by the FDA in 2017 described 414 medical device reports and 9 deaths associated with BIA-ALCL . Many case series have been reviewed and reported since, with data from France, Italy, The Netherlands, UK, Australia and the USA being prevalent [74, 75, 76, 77, 78, 79, 80]. Most recently, seven cases have been reported in Latin America . There are approximately 5–10 million women with breast implants worldwide with rates of BIA-ALCL being proportionately rare although difficult to put an exact figure to. Dependent on the study conducted, incidence rates range from 1 to 89 cases per million women with breast implants [82, 83]. This reaches a much higher incidence if one considers women with textured implants alone. Almost all cases reported to date have been associated with a breast implant of a textured surface at some point during the history of the patient; whilst rare cases have been reported in women with smooth implants, the patient had been in receipt of a textured implant at some stage [78, 84]. In addition, both saline and silicone filled implants have been implicated in patients with BIA-ALCL. The tumour cells generally present as a monoclonal expansion of CD30-positive cells, as an effusion within the fibrous capsule surrounding the implant .
3.1 Clinical course
BIA-ALCL appears to represent at least two clinical entities if not a spectrum of malignancies; patients present on most occasions with an indolent seroma with rarer incidences of invasive solid masses . Indeed, cases have been reported of tumour growth into the ribs with metastases to distant lymph nodes [85, 86].
3.2 Histopathological presentation and immunophenotype
Like sALCL, BIA-ALCL is characterised by CD30 expression on lymphoid cells, in the latter situation contained within the peri-prosthetic effusion [28, 87]. These cells can be detected by immunohistochemistry, cytology and flow cytometry of seroma fluid or any solid mass . A Th17/Th1 origin has been proposed whereby tumour cells secrete IFNγ, IL6, IL8, IL17 and TGFβ although a Th2 derivation has also been put forward [88, 89, 90].
3.3 Underlying genetic alterations
Like ALCL, ALK−, BIA-ALCL has not to date been associated with genomic events leading to activation of ALK. However, in concert with ALCL, ALK−, activating mutations of JAK/STAT proteins have been reported in a very few cases [91, 92]. Given the relative rarity of this disease, larger scale studies are required to elucidate the underlying genetics.
4. Primary cutaneous ALCL
While skin involvement can occur as an extranodal manifestation of sALCL, isolated cutaneous disease can also occur, although this is largely ALK-negative . Primary cutaneous ALCL belongs to the spectrum of CD30 positive lymphoproliferative disorders (LPDs) and like BIA-ALCL is largely indolent in nature. While largely affecting adults who present with isolated, ulcerating nodules, children can also develop pcALCL.
4.1 Clinical course
Like systemic ALCL, ALK−, cutaneous ALCL is also a disease of an older demographic with the majority of patients being over 50 years of age, yet is closer to ALCL, ALK+ in its prognosis, reaching a 5-year OS of over 90% . However, relapse is relatively common in this patient group occurring in as many as 30–40% of patients and some rare cases (12–16%) can progress to systemic disease [93, 94, 95]. Spontaneous regression has been reported, although in rare cases with partial regressions being more common .
4.2 Histopathological presentation and immunophenotype
Diagnosis can be difficult with other cutaneous T cell lymphomas such as lymphomatoid papulosis (LyP) and transformed mycosis fungoides (MF) providing differential diagnoses . However, like systemic ALCL, CD30 expression is a defining feature of this malignancy as it is for the other CD30-associated LPDs.
4.3 Underlying genetic alterations
Due to its relative rarity, sometimes-difficult diagnosis and indolent course, studies of the underlying genetics are few. However, limited studies have elucidated some of the genetic events that may be driving this disease process some of which are also common to sALCL. For example, as in sALCL, DUSP22-IRF4 rearrangements have been detected in 20–57% of pcALCL and ALK expression is seen in rare cases [19, 97, 98, 99, 100, 101]. In addition, aCGH has identified gains of 7q31 and losses of 6q16-21 as well as 13q34, collectively in 45% of examined patient specimens . As well as similarities to ALCL, ALK-negative with regards to DUSP22 translocations, upregulation of miR155 has also been observed in both pcALCL and sALCL, ALK− [61, 103]. The functional and clinical significance of these genetic events is still subject to investigation.
5. Treatment of ALCL
As for most peripheral T cell lymphomas, standard combination chemotherapy has been the mainstay of treatment for many years, specifically in the case of systemic disease . In contrast, the relatively indolent cutaneous and breast implant-associated forms are primarily treated by surgical removal . However, as this spectrum of diseases crosses age boundaries, there are age-specific differences in therapeutic approaches.
5.1 Treatment of children with ALCL
As mentioned before, the large majority of patients diagnosed with ALCL, ALK+ are children and young adults. As such, the therapeutic approach is tuned to this patient population with children receiving a combination of chemotherapeutic agents with survival rates in excess of 90% [10, 13, 14]. The ALCL99 trial, the largest trial ever to be conducted for children diagnosed with ALCL (n = 352) applied a therapeutic regimen consisting of a B cell protocol (based on NHL-BFM-B) with randomisation of vinblastine . The success of this trial has led to most centres adopting the ALCL99 treatment protocol. Additionally, the success of the ALCL99 trial and the plethora of biological data produced suggest that patients might be stratified according to ALK autoantibody titre and the presence of MDD as discussed above. Indeed, vinblastine monotherapy might be more appropriate for low risk patients reducing both acute and chronic side-effects of the combination chemotherapy protocol [104, 105].
5.2 Treatment of adults with ALCL
Adults with ALCL tend to be ALK− and are treated with the standard T cell lymphoma regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) although CHOEP (CHOP + etoposide) has been demonstrated to be superior in the treatment of adult ALCL, ALK+ patients . In the case of BIA-ALCL, surgical excision with complete capsulectomy is recommended and is often sufficient to induce remission particularly for patients that present with a contained seroma [85, 86]. However, patients with aggressive BIA-ALCL that has metastasised require radiotherapy if not chemotherapy, and anecdotal evidence suggests that upfront use of brentuximab vedotin (BV) may benefit these patients . In the case of pcALCL, localised excision and/or radiotherapy is largely prescribed due to the obvious skin presentation, although cases with multi-focal lesions may require more aggressive treatment involving chemotherapy [108, 109].
5.3 New and novel treatment options for ALCL
In the post-genomic era, targeted agents have become the mainstay of chemotherapy, largely in addition to standard cytotoxic drugs. In the case of ALCL, ALK+, inhibitors of ALK are the obvious choice and many have been developed since the discovery of ALK expression in Non-Small Cell Lung Cancer . The first ALK inhibitor to be developed was Pfizer’s PF-2341066, now known as crizotinib, a dual ALK/cMet inhibitor with efficacy in experimental models of ALCL, ALK+ . However, these drugs have been slow to make their way into the clinic for the treatment of ALCL, largely due to its relative rarity and paediatric presentation. A phase I study of crizotinib for children with relapsed/refractory ALK+ malignancies including ALCL, reported seven out of nine patients to achieve a complete response (CR) . A phase II expansion cohort showed overall response rates of 83 and 90% respectively for those children receiving crizotinib at dosages of 165 and 280 mg/m2 respectively . However, discontinuation of therapy has led to rapid relapse of both children and adults with ALCL, ALK+ questioning the required window of therapy .
Naturally, ALK inhibitors only apply to the therapy of ALCL, ALK+. In contrast, the common expression of CD30 on all ALCL sub-types means that targeted agents to this cell surface protein should be broadly applicable . In this vein, BV, an anti-CD30 antibody tethered to the microtubule inhibitor monomethyl auristatin E, has shown promising results in clinical trials, although relapse is again an issue with down-regulation of CD30 expression seen [115, 116, 117]. However, results of the Phase 3 ALCANZA trial for pcALCL and MF showed impressive results with an objective response rate of 67% in the BV arm (versus 20% in the standard treatment arm: methotrexate or bexarotene) . However, BV is not without its side-effects with peripheral neuropathy being prominent (affecting 67% of patients in the afore-mentioned trial) . Likewise, results of a Phase 2 trial of relapsed/refractory sALCL showed peripheral neuropathy to be a considerable side-effect in 91% of patients although a 5-year OS of 79% was achieved (69% CR, 80% ORR for ALK+ patients and 52% CR, 81% ORR for ALK−) . A randomised Phase 3 trial to establish the efficacy of BV in combination with cyclophosphamide, doxorubicin and prednisolone, in comparison to these chemotherapeutic agents given with vincristine in place of BV, is ongoing for the frontline treatment of CD30-positive lymphomas including ALCL (ECHELON 2; NCT01777152). Other potential therapeutic targets for the treatment of ALCL include PDGFR, JAK/STAT, PD-1/PDL1 and reactivation of p53 [42, 44, 120, 121]. Indeed, biological studies have identified a number of potential therapeutic targets, which in some cases, and with time, have been matched to available drugs. However, with relatively few patients, coupled with a good prognosis, at least for children with ALK+ systemic disease, it is difficult to formulate trials to test these agents.
A further approach given the immune response to ALK in patients with ALK-positive disease, is a vaccination strategy . This is especially relevant as ALK expression seems to be limited to tissues of neonatal origin suggesting that side-effects will be limited .
6. The origins and pathogenesis of ALCL: a common origin with distinct pathogenesis or different origins converging on a shared histopathology?
6.1 Cell of origin
Systemic ALCL presents in the periphery suggestive of a peripheral T cell origin, although as many as 50% of children show mediastinal involvement . In this latter vein, a thymic origin has been proposed whereby gene expression signatures associated with early thymic progenitors (ETP) are detected in ALCL cancer stem cells, in fitting with the detection of transcripts for the t(2;5)(p23;q35) translocation breakpoint product in 2% of cord blood specimens from healthy babies [124, 125]. In addition, studies of epigenetic signatures are in keeping with an ETP origin . As such, it is not inconceivable that ALCL, ALK+ has a thymic, perhaps
While ALCL, ALK+ is proposed to emerge from the thymus, a similar origin likely does not apply to ALK-negative disease, including pcALCL, BIA-ALCL and ALCL, ALK−. In these latter cases, circulating peripheral T cells are most probably the cells of origin given the older age of diagnosis and peripheral location, particularly with regards to BIA-ALCL and pcALCL. If this is the case, if the type of T cell that becomes transformed can be identified, this may give clues as to disease pathogenesis. While histopathology indicating an activated CD30-expressing T cell producing cytotoxic proteins, yet also often retaining CD4 expression, has given rise to a presumed cytotoxic T cell origin, recent data challenges this perception [29, 126]. Specifically, analysis of gene expression data suggests a Th17 origin, a T cell that usually responds to large extracellular infectious agents such as bacteria and is often implicated in autoimmune disease [89, 127]. However, given that ALCL often lack expression of TCR-related signalling proteins as well as a functional cell surface TCR, analogies to innate lymphoid cells (ILC), specifically ILC type 3 cells are also apparent . Naturally, the eventual cell phenotype is not necessarily reflective of the cell of origin with environmental events likely contributing to the final observed identity. In this regard, whether in ALCL, ALK+ this is shaped by ALK-mediated activities (or is the consequence of other induced (epi)genetic events) remains to be fully elucidated as it does for other ALCL sub-types. In evidence, it has been shown that NPM-ALK induces expression of cytotoxic proteins suggesting that their presence reflects the activities of this inherent transforming event rather than a property of the cell of origin, at least for ALCL, ALK+ . This would partly explain the ‘confused’ T cell phenotype with both helper and cytotoxic T cell properties apparent. Indeed, plasticity amongst helper T cell subsets is immense and is dependent on the relative expression levels of key transcription factors such as T-bet, RORγ, GATA-3 and Foxp3 as well as cytokines in the microenvironment . Hence, for a T cell aberrantly expressing a variety of genetic changes, embedded in specific inflammatory microenvironments, the resultant cell surface phenotype may no longer reflect the cell of origin.
Another factor to consider is genetic predisposition or health status of the patients whereby some, with for example, autoimmune disease or allergies and a preponderance of Th17 or Th1/Th2 cells respectively may be more at risk, with the resultant tumour phenotype dependent on this. In evidence, at least for BIA-ALCL Th1, Th2 and Th17 origins have been proposed based on the profile of secreted cytokines and expression of specific transcription factors, although of course none of these factors in isolation are necessarily truly indicative of the cell of origin, and as mentioned before, the contribution of the microenvironment cannot be discounted [88, 89, 90].
6.2 An infectious aetiology?
The common expression of CD30 on all entities of ALCL is suggestive of an infectious aetiology whereby activation of the underlying T cells triggers expression of this cell surface protein. However, individual cell surface proteins in isolation are not necessarily indicative of the cell of origin of any given cancer, which combined with the propensity of cancer cells to aberrantly up- or down-regulate expression of proteins according to evolutionary fitness necessitates further evidence to draw conclusive decisions. Yet, in evidence of an infectious aetiology, sALCL have been reported in the context of insect and tick bites, as well as bacterial infections on the surface of breast implants in BIA-ALCL and in association with cutaneous T cell lymphomas whereby TLRs 2, 4 and 7 are expressed by tumour cells [130, 131, 132]. Such infectious aetiologies would also produce an inflammatory microenvironment dictated by the infectious agent whereby cytokines, growth factors and many cell types involved in inflammation would be present and may contribute to disease pathogenesis. In this regard, the lymphohistiocytic subtype of sALCL is, as its name suggests, infiltrated with macrophages and many cytokines have been detected at elevated levels in patients diagnosed with ALCL, ALK+ [26, 133] (Figure 2).
ALCL is a diverse disease entity affecting a range of patients ranging from children to women with breast implants. What is clear, is that all ALCL share some common immunohistopathological features, most prominently CD30 expression, but the clinical courses of these diseases vary considerably from the indolent LPD, pcALCL through to aggressive, poor prognostic malignancies such as sALCL, ALK−. Our understanding of the underlying biology is improving year on year and has had a significant impact on clinical decision making including therapeutic approaches. While for many forms of ALCL, therapy has not altered considerably over the past decade, novel targeted approaches to treatment are entering the clinical arena ranging from monoclonal antibodies to kinase inhibitors. Indeed, we are now in the fortunate position whereby there are a plethora of therapeutic agents, but too few patients to trial them.
I would like to acknowledge all authors that have contributed to our understanding of ALCL who could not be cited due to page length restrictions.
Conflict of interest
The author declares no conflicts of interest.